Cidara Theraptcs Stock Price, News & Analysis

Cidara Therapeutics (NASDAQ: CDTX) has announced key leadership promotions effective May 1, 2025. Dr. Nicole Davarpanah has been elevated to Chief Medical Officer (CMO), while Corrina Pavetto has been promoted to Senior Vice President of Clinical Development. These appointments come as Cidara advances its influenza antiviral candidate CD388 through Phase 2b NAVIGATE trial and prepares for Phase 3. Dr. Davarpanah brings over a decade of clinical development experience, including 6 years at Genentech/Roche, and holds both M.D. and J.D. degrees. Pavetto contributes 25+ years of clinical research experience, particularly in infectious disease, with previous experience at BARDA overseeing influenza antiviral and vaccine development programs.

Cidara Therapeutics (Nasdaq: CDTX), a biotech company specializing in drug-Fc conjugate therapeutics through their proprietary Cloudbreak® platform, has announced their upcoming participation in The Citizens Life Sciences Conference.

The event details include:

• Conference: The Citizens Life Sciences Conference
• Date: Wednesday, May 7, 2025
• Time: 11:00 AM ET
• Format: Presentation

The presentation will be accessible via webcast, and a replay will be available in the Investors section of Cidara's website for at least 30 days. The company will also engage in one-on-one investor meetings during the event.

Cidara Therapeutics (CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its proprietary Cloudbreak® platform, has scheduled its first quarter 2025 financial results announcement for May 8, 2025. The results will be released after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time to discuss financial performance and provide operational updates.

Cidara Therapeutics (CDTX) has granted equity awards to new employee Timothy Alefantis under its 2020 Inducement Incentive Plan. The compensation package includes:

• Non-qualified stock options and RSUs totaling 27,000 shares
• Stock option exercise price set at $21.54 per share (closing price on March 31, 2025)
• Options vest over 4 years: 25% after first year, remaining in 36 monthly installments
• RSUs vest in 4 equal annual installments on quarterly vesting dates (March 10, June 10, September 10, or December 10)

These awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new employees who were not previously with Cidara.

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its Cloudbreak® platform, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company will deliver a presentation on Wednesday, April 9, 2025, at 11:00 AM ET. The presentation will be accessible via webcast, with a replay available in the Investors section of Cidara's website for 90 days following the event.

Additionally, Cidara's management team will engage in one-on-one investor meetings during the conference. Interested investors should coordinate with their Needham representatives to schedule meetings.

Cidara Therapeutics (CDTX) announced its participation in a important World Health Organization (WHO) panel discussion on H5N1 influenza preparedness and response, scheduled for March 19, 2025. The virtual meeting, focusing on research preparation and response to H5N1 influenza outbreaks, will feature Cidara in the 'Other pharmaceuticals as preventive tools' panel.

The company's chief scientific officer, Les Tari, Ph.D., will discuss CD388, their long-acting antiviral influenza preventative currently undergoing a 5,000-subject Phase 2b study. The drug has shown promising results against all influenza A and B strains, including H5N1, in preclinical studies.

The WHO meeting aims to address H5N1, a highly infectious avian influenza virus affecting birds and mammals, including humans. Key objectives include identifying knowledge gaps, outlining regulatory pathways for mRNA vaccines, and reviewing therapeutics such as monoclonal antibodies and long-acting antivirals.

Cidara Therapeutics (CDTX) announced two upcoming presentations at the 38th International Conference on Antiviral Research (ICAR) focusing on their drug candidate CD388 for influenza prevention.

The first presentation covers the Phase 2b NAVIGATE trial, which has completed enrollment of over 5,000 participants in the US and UK. The trial evaluates CD388's safety and preventative efficacy, administered via subcutaneous injection. Previous Phase 1 and 2a data showed the drug was well-tolerated and efficacious in healthy volunteers.

The second presentation addresses modeling of seasonal influenza variations to support clinical dose selection. The research demonstrates that while standard proportion tests are sensitive to seasonal flu variations, their model-based analysis improves decision power for CD388's Phase 3 dose selection.

Cidara Therapeutics (CDTX) has published preclinical data for CD388, their influenza drug-Fc conjugate (DFC), in Nature Microbiology. The study demonstrates CD388's potential as a universal preventative treatment for both influenza A and B strains.

The research highlights CD388's key capabilities including:

• Potent activity against all influenza strains, including H5N1 (bird flu)
• Effectiveness against neuraminidase inhibitor-resistant strains
• Low resistance development potential
• Similar efficacy in both immune-competent and immune-compromised models

The company is currently conducting a Phase 2b NAVIGATE trial with approximately 5,000 subjects to evaluate CD388 as a single-dose preventative treatment for seasonal influenza in healthy unvaccinated adults during the 2024-2025 flu season.

Cidara Therapeutics (CDTX) reported its Q4 and full year 2024 financial results, marking a transformational year with significant developments. The company completed enrollment of 5,000 subjects in its Phase 2b NAVIGATE trial for CD388, a long-acting universal influenza preventative drug.

Key financial highlights include: Cash position of $196.2 million as of December 31, 2024, bolstered by a $105.0 million private placement in November 2024 and earlier $240.0 million raised in April. Collaboration revenue decreased to $1.3 million for 2024 from $23.3 million in 2023. R&D expenses increased to $71.9 million in 2024 from $36.8 million in 2023.

The company reacquired rights to the CD388 program and may consider an early analysis of efficacy data in first half 2025 due to severe flu season. Net loss widened to $169.8 million in 2024 from $22.9 million in 2023, primarily due to increased R&D expenses and an $85.0 million upfront payment to Janssen.